John Hamm

John Frederick Hamm (born April 8, 1938) is a Canadian physician and politician, who served as the 25th premier of Nova Scotia from 1999 to 2006. Provided by Wikipedia
Showing 1 - 6 results of 6 for search 'John Hamm', query time: 0.03s Refine Results
  1. 1
    Phase I study of allogeneic monocyte-derived inflammatory dendritic cells in combination with pembrolizumab

    Phase I study of allogeneic monocyte-derived inflammatory dendritic cells in combination with pembrolizumab by Jared Weiss, Douglas Laux, David Bajor, Albert C. Lockhart, John Hamm, Jeroen Rovers, Alex Karlsson-Parra

    Published 2024-12-01
    Get full text
    Article
  2. 2
    735 Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer

    735 Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer by Rachel E Sanborn, Trisha M Wise-Draper, Marc Van Dijk, Breelyn Wilky, Anthony El-Khoueiry, John Hamm, Benjamin Garmezy, Benedito Carneiro, Jamie Moon, Sue Ryu, Irene R Ramos, Marco A Purbhoo, Dave SB Hoon

    Published 2023-11-01
    Article
  3. 3
    748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors

    748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors by Daniel Olson, Manish Sharma, Erminia Massarelli, Jonathan Thompson, Rachel E Sanborn, Ralph J Hauke, Anthony W Tolcher, Elizabeth Davis, Conor Steuer, Muhammad Furqan, John Hamm, Doug Laux, David Berz, Wade T Iams, Vasily Andrianov, Brianne O’Neill, Yaiza Diaz De Durana

    Published 2023-11-01
    Article
  4. 4
    742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors

    742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors by David Hong, Manish Sharma, Erminia Massarelli, Heather Kinkead, Naomi B Haas, Rachel E Sanborn, Ralph J Hauke, Anthony W Tolcher, Neal Akhave, Jong Chul Park, Jennifer Carlisle, John Hamm, Alexander I Spira, David Berz, Vasily Andrianov, Brianne O’Neill, Justin A Call, Frank Yung-Chin Tsai, D Ross Camidge

    Published 2023-11-01
    Article
  5. 5
    599 Single-agent safety and activities of target-preserving anti-CTLA-4 antibody gotistobart (ONC-392/BNT316) in PD-(L)1 resistant metastatic NSCLC and population PK analysis in patients with solid tumors

    599 Single-agent safety and activities of target-preserving anti-CTLA-4 antibody gotistobart (ONC-392/BNT316) in PD-(L)1 resistant metastatic NSCLC and population PK analysis in pa... by Yang Liu, Dan Chen, Mark Goldstein, John Yang, Mei Tang, Rohit Joshi, David Carbone, Siwen Hu-Lieskovan, Zihai Li, Tianhong Li, Meredith McKean, Kai He, Julio Peguero, Pan Zheng, Hung-Yen Chou, Edward Arrowsmith, John Hamm, AIwu He, Satish Shah, Alexander I Spira, Rama Balaraman, Adriana millillo-Naranine

    Published 2023-11-01
    Article
  6. 6
    Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial

    Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III I... by Enriqueta Felip, Hiroshi Tanaka, Silvia Novello, Hao Xu, Heather Wakelee, Barbara Gitlitz, Martin Reck, Wei Zou, Elizabeth Bennett, Mark McCleland, Caicun Zhou, Satoshi Oizumi, Anna Kryzhanivska, Virginia McNally, Marcus Ballinger, Meghna Das Thakur, Steven L McCune, John Hamm, Minu K Srivastava, Nasser Altorki, Rüdiger Liersch

    Published 2023-10-01
    Get full text
    Article

Search Tools: